Sign in
IKNA Stock Price, Chart, Stats & News
Ikena Oncology, Inc.
Save
718.82M
Market cap
–
Current P/E
–
Forward P/E
IKNA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.77% |
ROA | -61.55% |
ROE | -45.32% |
D/E | – |
Interest coverage ratio | – |
IKNA valuation
P/E | – |
P/S | – |
P/B | 10.93x |
P/CF | -17.31x |
P/FCF | -15.02x |
P/OCF | -17.31x |
PEG | -0.16x |
EV multiple | -13.92x |
About
Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway.
Similar securities
Based on sector and market capitalization
Report issue